DK3369435T3 - Sammensætning til behandling af inflammatorisk ledsygdom - Google Patents

Sammensætning til behandling af inflammatorisk ledsygdom Download PDF

Info

Publication number: DK3369435T3
Authority: DK; Denmark
Prior art keywords: treatment; composition; inflammatory disease; inflammatory; disease
Prior art date: 2013-07-18

Application number

DK18167083T

Other languages

English (en)

Inventor

Robert Landry

Raymond A Chavez

Linda R Watkins

Original Assignee

Xalud Therapeutics Inc

Univ Colorado Regents

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-07-18

Filing date

2014-07-17

Publication date

2019-11-25

2014-07-17 Application filed by Xalud Therapeutics Inc, Univ Colorado Regents filed Critical Xalud Therapeutics Inc

2019-11-25 Application granted granted Critical

2019-11-25 Publication of DK3369435T3 publication Critical patent/DK3369435T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0091—Purification or manufacturing processes for gene therapy compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5428—IL-10

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Biotechnology (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Rheumatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Toxicology (AREA)
Physical Education & Sports Medicine (AREA)
Pain & Pain Management (AREA)
Manufacturing & Machinery (AREA)
Orthopedic Medicine & Surgery (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DK18167083T 2013-07-18 2014-07-17 Sammensætning til behandling af inflammatorisk ledsygdom DK3369435T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361847851P	2013-07-18	2013-07-18
EP14826787.5A EP3021873B8 (en)	2013-07-18	2014-07-17	Composition for the treatment of inflammatory joint disease

Publications (1)

Publication Number	Publication Date
DK3369435T3 true DK3369435T3 (da)	2019-11-25

Family

ID=52346725

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK18167083T DK3369435T3 (da)	2013-07-18	2014-07-17	Sammensætning til behandling af inflammatorisk ledsygdom
DK14826787.5T DK3021873T3 (da)	2013-07-18	2014-07-17	Sammensætning til behandling af inflammatorisk ledsygdom

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK14826787.5T DK3021873T3 (da)	2013-07-18	2014-07-17	Sammensætning til behandling af inflammatorisk ledsygdom

Country Status (15)

Country	Link
US (4)	US10512672B2 (da)
EP (2)	EP3369435B1 (da)
JP (4)	JP2016525522A (da)
CY (2)	CY1120946T1 (da)
DK (2)	DK3369435T3 (da)
ES (2)	ES2700826T3 (da)
HR (2)	HRP20181913T1 (da)
HU (2)	HUE042463T2 (da)
LT (2)	LT3021873T (da)
PL (2)	PL3021873T3 (da)
PT (2)	PT3021873T (da)
RS (2)	RS59735B1 (da)
SI (2)	SI3021873T1 (da)
SM (2)	SMT201800655T1 (da)
WO (1)	WO2015009955A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2700826T3 (es)	2013-07-18	2019-02-19	Xalud Therapeutics Inc	Composición para el tratamiento de la enfermedad inflamatoria articular
WO2017184933A1 (en) *	2016-04-22	2017-10-26	Xalud Therapeutics, Inc.	Methods and compositions to enhance the anti-inflammatory effects of interleukin 10
EP4172184A2 (en) *	2020-06-26	2023-05-03	Amgen Inc.	Il-10 muteins and fusion proteins thereof
US20250051412A1 (en) *	2021-12-16	2025-02-13	Xalud Therapeutics, Inc.	Dosing regimen for il-10 encoding expression construct

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6673776B1 (en)	1989-03-21	2004-01-06	Vical Incorporated	Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
US5231012A (en)	1989-06-28	1993-07-27	Schering Corporation	Nucleic acids encoding cytokine synthesis inhibitory factor (interleukin-10)
US6217857B1 (en)	1989-06-28	2001-04-17	Schering Corporation	Cytokine synthesis inhibitory factor (IL-10) and pharmaceutical compositions thereof
US6018036A (en)	1990-06-29	2000-01-25	Schering Corporation	Nucleic acids encoding cytokine synthesis inhibitory factor (Interleukin-10)
DE69316921T2 (de)	1992-08-20	1998-06-04	Schering Corp., Kenilworth, N.J.	Neue verwendungen für il-10
US5922018A (en)	1992-12-21	1999-07-13	Artann Corporation	Method for using a transrectal probe to mechanically image the prostate gland
US5373317B1 (en)	1993-05-28	2000-11-21	Welch Allyn Inc	Control and display section for borescope or endoscope
ATE304604T1 (de)	1993-06-24	2005-09-15	Frank L Graham	Adenovirus vektoren für gentherapie
US6652850B1 (en)	1993-09-13	2003-11-25	Aventis Pharmaceuticals Inc.	Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity
BR9407956A (pt)	1993-10-25	1996-11-26	Canji Inc	Composiçao farmacêutica vetor de express o de adenovirus recombinante e kit par reduzir a proliferaçao de células tumorais
US7252989B1 (en)	1994-04-04	2007-08-07	Board Of Regents, The University Of Texas System	Adenovirus supervector system
WO1996001318A1 (en)	1994-07-05	1996-01-18	Steeno Research Group A/S	Immunomodulators
JPH11501506A (ja)	1994-12-12	1999-02-09	ベスイスラエルデアコネスメディカルセンター	キメラ型サイトカインおよびその利用
US5716804A (en)	1995-04-19	1998-02-10	Schering Corporation	Mammalian interleukin-10 (IL-10) super-activating receptors; and variants
WO1998024469A1 (en)	1996-12-05	1998-06-11	University Of Florida	Il-10 and tgf-beta for treating autoimmune disease
US6201880B1 (en)	1996-12-31	2001-03-13	Electro-Optical Sciences	Method and apparatus for electronically imaging a tooth through transillumination by light
US5783567A (en)	1997-01-22	1998-07-21	Pangaea Pharmaceuticals, Inc.	Microparticles for delivery of nucleic acid
US6013253A (en)	1997-08-15	2000-01-11	Amgen, Inc.	Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
US20030044384A1 (en)	1997-10-09	2003-03-06	Pro-Virus, Inc.	Treatment of neoplasms with viruses
AU3063899A (en)	1998-03-17	1999-10-11	Schering Corporation	Use of il-10 to treat major depressive disorder
CA2295510A1 (en)	1998-05-06	1999-11-11	Transgene S.A.	Use of a nuclease inhibitor or interleukin-10 (il-10) for the preparation of a therapeutic composition for improving transfection of a polynucleotide into a cell and compositions useful in gene therapy
US6428985B1 (en)	1998-12-02	2002-08-06	The Regents Of The University Of Michigan	Immunosuppressive structural definition of IL-10
US6982089B2 (en)	1999-02-24	2006-01-03	Tact Ip, Llc	Cytokine antagonists for neurological and neuropsychiatric disorders
US6165754A (en)	1999-06-08	2000-12-26	Cornell Research Foundation, Inc.	Method of expressing an exogenous nucleic acid
US20050129669A1 (en)	1999-06-21	2005-06-16	Transkaryotic Therapies, Inc., A Massachusetts Corporation	DNA construct for effecting homologous recombination and uses thereof
EP1278551A2 (en)	2000-04-21	2003-01-29	Vical Incorporated	Compositions and methods for (in vivo) delivery of polynucleotide-based therapeutics
AU2002217929A1 (en)	2000-11-28	2002-06-11	Sangamo Biosciences, Inc.	Modulation of gene expression using insulator binding proteins
EP1341522B1 (de) *	2000-12-13	2005-11-16	Merckle Gmbh	Mikropartikel mit verbessertem freisetzungsprofil und verfahren zu deren herstellung
WO2002083080A2 (en) *	2001-04-17	2002-10-24	Genetix Pharmaceuticals, Inc.	Method of treating arthritis using lentiviral vectors in gene therapy
US20030166593A1 (en)	2001-04-30	2003-09-04	Kenneth Chien	Non-viral vesicle vector for cardiac specific gene delivery
JP4578735B2 (ja)	2001-08-28	2010-11-10	オリンパス株式会社	内視鏡画像ファイリングシステム
JP2003146909A (ja)	2001-11-07	2003-05-21	Children's Hospital Of Philadelphia	治療用ポリペプチドに対する免疫寛容の誘導
CA2361462A1 (en)	2001-11-07	2003-05-08	Katherine A. High	Induction of tolerance to a therapeutic polypeptide
AU2003209226A1 (en)	2002-01-11	2003-07-30	Michael Tennant	Adiponectin gene therapy
AU2003221745A1 (en)	2002-04-19	2003-11-03	University Of Florida	rAAV VECTOR-BASED COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MAMMALIAN DISEASES
WO2004042001A2 (en) *	2002-05-17	2004-05-21	Emory University	Virus-like particles, methods of preparation, and immonogenic compositions
GB0212648D0 (en)	2002-05-31	2002-07-10	Immunoclin Lab Ltd	Treatment with cytokines
US20040186357A1 (en)	2002-08-20	2004-09-23	Welch Allyn, Inc.	Diagnostic instrument workstation
AU2003268323A1 (en)	2002-08-29	2004-03-19	The Board Of Trustees Of The Leland Stanford Junior University	Circular nucleic acid vectors, and methods for making and using the same
US20040142893A1 (en)	2002-10-21	2004-07-22	Uichi Ikeda	Methods for treating and preventing vascular disease
US7261882B2 (en)	2003-06-23	2007-08-28	Reagents Of The University Of Colorado	Methods for treating neuropathic pain by administering IL-10 polypeptides
US7530946B2 (en)	2003-08-15	2009-05-12	Scimed Life Systems, Inc.	Compact endoscope
US7276486B2 (en)	2004-03-15	2007-10-02	Kimberly-Clark Worldwide, Inc.	Compositions for vaginal treatment
WO2006007529A2 (en) *	2004-07-01	2006-01-19	University Of Pittsburgh Of The Commonwealth System For Higher Education	Immunosuppressive exosomes
US20060073119A1 (en)	2004-09-01	2006-04-06	Avigen, Inc.	Methods for treating neurodegenerative disorders
EP1901769A2 (en)	2005-05-02	2008-03-26	Avigen, Inc.	Use of cytokine-derived peptides in treatment of pain and neurodegenerative disease
ATE452908T1 (de) *	2005-05-31	2010-01-15	Univ Colorado	Il-10 mutante
LT2816118T (lt)	2005-05-31	2018-12-10	The Regents Of The University Of Colorado, A Body Corporate	Genų pristatymo būdai
US20080274202A1 (en)	2005-08-01	2008-11-06	Kraig Richard P	Compositions and Method for Brain Specific Targeted Delivery of Therapeutic Agents
WO2008109806A2 (en)	2007-03-08	2008-09-12	Massachusetts Institute Of Technology	Electrostatic coating of particles for drug delivery
US7846428B2 (en)	2007-10-05	2010-12-07	Merial Limited	Articular cartilage gene therapy with recombinant vector encoding BMP-7
US9315825B2 (en)	2010-03-29	2016-04-19	The Trustees Of The University Of Pennsylvania	Pharmacologically induced transgene ablation system
AU2011344030B2 (en)	2010-12-15	2017-03-30	Olatec Therapeutics Llc	3-methanesulfonylpropionitrile for treating inflammation and pain
US20150044281A1 (en)	2012-01-06	2015-02-12	The Regents Of The University Of Colorado, A Body Corporate	Methods for the treatment of multiple sclerosis and other demyelinating disorders
ES2700826T3 (es)	2013-07-18	2019-02-19	Xalud Therapeutics Inc	Composición para el tratamiento de la enfermedad inflamatoria articular
WO2017184933A1 (en)	2016-04-22	2017-10-26	Xalud Therapeutics, Inc.	Methods and compositions to enhance the anti-inflammatory effects of interleukin 10

2014
- 2014-07-17 ES ES14826787T patent/ES2700826T3/es active Active
- 2014-07-17 DK DK18167083T patent/DK3369435T3/da active
- 2014-07-17 PT PT14826787T patent/PT3021873T/pt unknown
- 2014-07-17 DK DK14826787.5T patent/DK3021873T3/da active
- 2014-07-17 ES ES18167083T patent/ES2760902T3/es active Active
- 2014-07-17 PT PT181670837T patent/PT3369435T/pt unknown
- 2014-07-17 SI SI201430972T patent/SI3021873T1/sl unknown
- 2014-07-17 RS RS20191473A patent/RS59735B1/sr unknown
- 2014-07-17 PL PL14826787T patent/PL3021873T3/pl unknown
- 2014-07-17 RS RS20181419A patent/RS57974B1/sr unknown
- 2014-07-17 LT LTEP14826787.5T patent/LT3021873T/lt unknown
- 2014-07-17 PL PL18167083T patent/PL3369435T3/pl unknown
- 2014-07-17 SI SI201431402T patent/SI3369435T1/sl unknown
- 2014-07-17 WO PCT/US2014/047071 patent/WO2015009955A1/en active Application Filing
- 2014-07-17 SM SM20180655T patent/SMT201800655T1/it unknown
- 2014-07-17 JP JP2016527107A patent/JP2016525522A/ja not_active Withdrawn
- 2014-07-17 US US14/905,915 patent/US10512672B2/en active Active
- 2014-07-17 HU HUE14826787A patent/HUE042463T2/hu unknown
- 2014-07-17 EP EP18167083.7A patent/EP3369435B1/en active Active
- 2014-07-17 LT LTEP18167083.7T patent/LT3369435T/lt unknown
- 2014-07-17 SM SM20190657T patent/SMT201900657T1/it unknown
- 2014-07-17 HU HUE18167083A patent/HUE046944T2/hu unknown
- 2014-07-17 EP EP14826787.5A patent/EP3021873B8/en active Active
2018
- 2018-11-16 HR HRP20181913TT patent/HRP20181913T1/hr unknown
- 2018-11-28 CY CY181101297T patent/CY1120946T1/el unknown
2019
- 2019-10-31 US US16/670,987 patent/US20200093892A1/en not_active Abandoned
- 2019-11-01 JP JP2019199475A patent/JP7066669B2/ja active Active
- 2019-11-12 HR HRP20192043TT patent/HRP20192043T1/hr unknown
- 2019-12-03 CY CY20191101267T patent/CY1122673T1/el unknown
2021
- 2021-11-05 JP JP2021180762A patent/JP2022031682A/ja active Pending
2022
- 2022-06-21 US US17/845,101 patent/US20220313785A1/en not_active Abandoned
2023
- 2023-01-25 US US18/159,161 patent/US20230158114A1/en active Pending
2024
- 2024-11-29 JP JP2024207852A patent/JP2025023096A/ja active Pending

Also Published As

Publication number	Publication date
DK3021873T3 (da)	2018-12-17
WO2015009955A1 (en)	2015-01-22
CY1122673T1 (el)	2021-03-12
RS59735B1 (sr)	2020-02-28
HRP20181913T1 (hr)	2019-01-11
SI3369435T1 (sl)	2020-03-31
EP3021873B1 (en)	2018-09-05
ES2760902T3 (es)	2020-05-18
LT3369435T (lt)	2020-01-10
HUE042463T2 (hu)	2019-07-29
RS57974B1 (sr)	2019-01-31
PL3021873T3 (pl)	2019-01-31
SMT201900657T1 (it)	2020-01-14
US10512672B2 (en)	2019-12-24
PT3369435T (pt)	2019-12-05
EP3369435B1 (en)	2019-09-04
EP3021873A4 (en)	2016-11-30
JP2022031682A (ja)	2022-02-22
SMT201800655T1 (it)	2019-01-11
US20160235816A1 (en)	2016-08-18
EP3021873A1 (en)	2016-05-25
PT3021873T (pt)	2018-12-10
EP3369435A1 (en)	2018-09-05
JP2016525522A (ja)	2016-08-25
EP3021873B8 (en)	2018-10-24
PL3369435T3 (pl)	2020-04-30
ES2700826T3 (es)	2019-02-19
US20230158114A1 (en)	2023-05-25
JP2020037562A (ja)	2020-03-12
LT3021873T (lt)	2018-11-26
HUE046944T2 (hu)	2020-03-30
SI3021873T1 (sl)	2018-12-31
JP7066669B2 (ja)	2022-05-13
CY1120946T1 (el)	2019-12-11
JP2025023096A (ja)	2025-02-14
US20200093892A1 (en)	2020-03-26
HRP20192043T1 (hr)	2020-02-07
US20220313785A1 (en)	2022-10-06

Publication	Publication Date	Title
CY2021007I2 (el)	2021-06-25	Συνθεσεις χρησιμες για τη θεραπεια διαταραχων που σχετιζονται με kit
DK3030323T3 (da)	2019-07-15	Kdm1a-inhibitorer til behandlingen af sygdom
DK2968208T3 (da)	2022-08-22	Behandling af kataplexi
HK1222136A1 (zh)	2017-06-23	交聯的絲-透明質酸組合物
DK2984166T3 (da)	2020-07-20	Sammensætninger til behandling af mpsi
DK3043816T3 (da)	2019-10-14	Anti-b7-h1-antistoffer til behandling af tumorer
DK3076967T3 (da)	2021-10-25	Fremgangsmåder til behandling af residuelle symptomer på skizofreni
DK2981255T3 (da)	2022-11-14	Terapeutiske anvendelser af empagliflozin
DK3027618T3 (da)	2020-10-12	Polymorf af syk-hæmmere
DK2964315T3 (da)	2019-01-02	System til behandling af neuromotorisk dysfunktion
DK2961766T3 (da)	2019-07-15	Kvantificering af vaccinesammensætninger
DK2968221T3 (da)	2019-08-05	Farmaceutisk sammensætning af s-ketaminhydrochlorid
DK3021838T3 (da)	2020-08-24	Behandling af fedme
DK3626270T3 (da)	2024-01-15	Behandling af kardiovaskulære sygdomme
DK3106150T3 (da)	2021-11-01	Forbedrede farmaceutiske sammensætninger af pimobendan
DK3027750T3 (da)	2019-07-15	Biokatalytisk sammensætning
DK2961378T3 (da)	2019-11-25	Fremgangsmåder til behandlingen af mitochondrisk sygdom
PT3071638T (pt)	2017-06-09	Composição de cianoacrilato
DK3010895T3 (da)	2017-11-20	Fremgangsmåde til fremstilling af 4-propargyleret aminobenzoxazinoner
LT3007726T (lt)	2020-09-10	Tautopatijos gydymo būdai
DK3021839T3 (da)	2021-07-26	Sammensætninger for behandling af fibrose
DK3511004T3 (da)	2024-09-23	Kombineret præparat til behandling af cancer
EP2945942A4 (en)	2016-08-03	Voriconazole IMMUNOASSAY
DK2985275T3 (da)	2020-01-20	Fremgangsmåde til oprensning af beta-hydroxy-beta-methylsmørsyre
DK3052102T3 (da)	2020-03-09	Sammensætninger til behandling af cancere